Related Experiment Videos
[Catecholamines and beta-blockers for the treatment of heart failure]
M Takahashi1, T Yamada, M Kinoshita
1First Department of Internal Medicine, Shiga University of Medical Science.
Insights
Catecholamines like dopamine and dobutamine improve heart function in acute heart failure but tachyphylaxis limits their use. Molecular mechanisms of beta-blocker therapy are also discussed.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Context:
- Cardiac beta-adrenoceptors mediate key heart functions.
- Therapeutic catecholamines show reduced efficacy in failing myocardium.
- Failing human myocardium exhibits beta-adrenoceptor downregulation and G protein uncoupling.
Purpose:
- To explain the effects of catecholamines on cardiac function.
- To discuss the limitations of catecholamine therapy in acute heart failure.
- To explore the molecular mechanisms underlying beta-blocker therapy.
Summary:
- Catecholamines induce positive inotropic, chronotropic, dromotropic, and lucinotropic effects via cardiac beta-adrenoceptors.
- Acute heart failure treatment with intravenous catecholamines (dopamine, dobutamine) offers rapid improvement but is limited by tachyphylaxis within 72 hours.
- Dopamine's DA1-receptor activity enhances renal blood flow, while dobutamine is more effective than dopamine in reducing pulmonary capillary wedge pressure (PCWP).
Impact:
- Provides insights into catecholamine efficacy and limitations in heart failure.
- Highlights the molecular basis of receptor dysfunction in failing hearts.
- Discusses therapeutic strategies and their underlying mechanisms for heart failure management.
Abstract:
Catecholamines bind to cardiac beta-adrenoceptor to introduce positive inotropic, chronotropic, dromotropic and lucinotropic effects of the heart. Therapeutic catecholamines causes less effects to failing myocardium in comparison to normal myocardium. Down-regulation of cardiac beta-adrenoceptor (decrease in receptor number) and uncoupling of beta-adrenoceptor to G protein (increase in Gi alpha) have been demonstrated in failing human myocardium. Rapid improvement can be obtained in cardiac function by intravenous catecholamines, usually with dopamine and/or dobutamine in patients with acute heart failure. But, tachyphylaxis occurs in 72 hours which limits usefulness of the drugs. Dopamine has DA1-receptor activity which increases renal blood flow and natriuresis. Dobutamine is superior to dopamine in positive lucinotropic effects in reducing PCWP in patients with heart failure. Mechanisms of beta blocker therapy with special reference to molecular mechanisms are discussed.